Skip to main navigation Skip to search Skip to main content

Evidence for the Additional Health Benefits Associated with Phosphodiesterase 5 Inhibitors when Used for Treating Erectile Dysfunction, with a Focus on Prostate Cancer Patients and Other Associated Conditions

  • Alexandra Naranjo
  • , Geoffrey Ian Hackett
  • , Sophie Smith
  • , Harley Stephens
  • , William Kinnaird
  • , Mike Kirby
    • Prostate Cancer UK
    • University Hospitals Bristol and Weston NHS Foundation Trust
    • University College London Hospitals NHS Foundation Trust

    Research output: Contribution to journal › Review article › peer-review

    2 Downloads (Pure)

    Abstract

    Erectile dysfunction (ED) affects the majority of prostate cancer (PCa) patients. Although phosphodiesterase 5 inhibitors (PDE5i) are the first-line treatment for ED and are strongly supported by evidence as safe and effective, they remain underutilised in PCa patients. Furthermore, there is a large evidence base that supports the association of PDE5i with favourable clinical outcomes in several different health conditions that are also often considered co-morbidities for men with PCa. We present this review to examine the evidence on favourable clinical outcomes associated with PDE5i use in a range of urological, cardiovascular, metabolic, and skeletal conditions. In men who have been treated for PCa, these co-morbidities are common and may even be exacerbated by treatment itself. The evidence base suggests that PDE5i could potentially co-treat several comorbidities in men treated for PCa in addition to ED, provided high-quality randomised controlled trials replicate and confirm the findings of observational studies and animal models. If validated, PDE5i may be prescribed in appropriately selected patients and exert its beneficial effects in these men post PCa treatment, not only improving health outcomes but also quality of life.
    Original languageEnglish
    Pages (from-to)582-592
    Number of pages11
    JournalThe World Journal of Men's Health
    Volume44
    Issue number3
    Early online date13 Feb 2026
    DOIs
    Publication statusPublished - 1 Jul 2026

    Bibliographical note

    Copyright © 2026 Korean Society for Sexual Medicine and Andrology.
    This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Erectile dysfunction
    • Phosphodiesterase inhibitor
    • Prostatic neoplasms
    • Therapeutics

    Fingerprint

    Dive into the research topics of 'Evidence for the Additional Health Benefits Associated with Phosphodiesterase 5 Inhibitors when Used for Treating Erectile Dysfunction, with a Focus on Prostate Cancer Patients and Other Associated Conditions'. Together they form a unique fingerprint.

    Cite this